Despite an improvement in prognosis classification, mostly based on the identification of gene mutations such as NPM1, FLT3, or CEBPA, outcomes in CN-AML remain heterogeneous, underlying the wide diversity of this AML subset. This evidence concerns the gene CEBPA and acute myeloid leukemia.